Evrysdi Archives -

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with

Biogen looks beyond Spinraza in SMA with Ionis deal

https://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/

Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

https://pharmaphorum.com/news/nice-reaches-a-deal-with-roche-on-access-to-oral-sma-drug-evrysdi/

Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing

Roche builds evidence for Evrysdi’s benefits in younger SMA patients

https://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance,

NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group

https://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/

Roche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

https://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/

Evrysdi